Extracolonic Manifestations of Lynch Syndrome

 

 Buy Article Permissions and Reprints

Abstract

Lynch syndrome has classically been defined by several predominant malignancies. Initial clinical criteria for diagnosis of Lynch syndrome would miss 40% of affected individuals. As time has passed, our understanding of Lynch syndrome has evolved and will continue to do so. The number of cancer types that are included in the Lynch phenotype is growing. This has allowed clinicians to redefine Lynch syndrome, at risk populations, screening needs, and diagnostic criteria. Inclusion of extracolonic malignancies and alternative genetic pathways gives new insight into the true prevalence and penetrance of Lynch syndrome.

• References

• 1 Ponz de Leon M, Bertario L, Genuardi M , et al; Report from the Italian Association for the Study of Hereditary Colorectal Tumors Consensus Group. Identification and classification of hereditary nonpolyposis colorectal cancer (Lynch syndrome): adapting old concepts to recent advancements. Report from the Italian Association for the study of Hereditary Colorectal Tumors Consensus Group. Dis Colon Rectum 2007; 50 (12) 2126-2134
  CrossrefPubMedGoogle Scholar
• 2 Lin KM, Shashidharan M, Ternent CA , et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum 1998; 41 (4) 428-433
  CrossrefPubMedGoogle Scholar
• 3 Vasen HFA, Offerhaus GJ, den Hartog Jager FC , et al. The tumor spectrum in HNPCC: a study of 24 kindred in the Netherlands. Int J Cancer 1990; 46: 31-34
  CrossrefPubMedGoogle Scholar
• 4 da Silva FC, de Oliveira LP, Santos EM , et al. Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer 2010; 9 (4) 563-570
  CrossrefPubMedGoogle Scholar
• 5 Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71 (3) 677-685
  CrossrefPubMedGoogle Scholar
• 6 Akiyama Y, Sato H, Yamada T , et al. Germline mutation of the hMSH6 gene in an atypical hereditary non-polyposis colorectal cancer kindred. Clin Cancer Res 1997; 57: 3920-3923
  PubMedGoogle Scholar
• 7 Park YJ, Shin KH, Park JG. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clin Cancer Res 2000; 6 (8) 2994-2998
  PubMedGoogle Scholar
• 8 Suchy J, Cybulski C, Wokołorczyk D , et al. CHEK2 mutations and HNPCC-related colorectal cancer. Int J Cancer 2010; 126 (12) 3005-3009
  PubMedGoogle Scholar
• 9 Risinger JI, Barrett JC, Watson P, Lynch HT, Boyd J. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 1996; 77 (9) 1836-1843
  CrossrefPubMedGoogle Scholar
• 10 Jensen UB, Sunde L, Timshel S , et al. Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 2010; 120 (3) 777-782
  CrossrefPubMedGoogle Scholar
• 11 Boyd J, Rhei E, Federici MG , et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 1999; 53 (1) 87-91
  CrossrefPubMedGoogle Scholar
• 12 Scott RJ, McPhillips M, Meldrum CJ , et al. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet 2001; 68 (1) 118-127
  CrossrefPubMedGoogle Scholar
• 13 Vasen HFA, Morreau H, Nortier JWR. Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer?. Am J Hum Genet 2001; 68 (6) 1533-1535
  CrossrefPubMedGoogle Scholar
• 14 Cybulski C, Górski B, Huzarski T , et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75 (6) 1131-1135
  CrossrefPubMedGoogle Scholar
• 15 Meijers-Heijboer H, Wijnen J, Vasen H , et al. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003; 72 (5) 1308-1314
  CrossrefPubMedGoogle Scholar
• 16 Wasielewski M, Vasen H, Wijnen J , et al. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer. Clin Cancer Res 2008; 14 (15) 4989-4994
  CrossrefPubMedGoogle Scholar
• 17 Lenz DL, Harpster LE. Urothelial carcinoma in a man with hereditary nonpolyposis colon cancer. Rev Urol 2003; 5 (1) 49-53
  PubMedGoogle Scholar
• 18 Valenzuela CD, Moore HG, Huang WC , et al. Three synchronous primary carcinomas in a patient with HNPCC associated with a novel germline mutation in MLH1: case report. World J Surg Oncol 2009; 7: 94 . Available at http://www.wjso.com/content/7/1/97
  CrossrefPubMedGoogle Scholar
• 19 Goecke T, Schulmann K, Engel C , et al; German HNPCC Consortium. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol 2006; 24 (26) 4285-4292
  CrossrefPubMedGoogle Scholar
• 20 Watson P, Vasen HFA, Mecklin JP , et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123 (2) 444-449
  CrossrefPubMedGoogle Scholar
• 21 Wagner A, Hendriks Y, Meijers-Heijboer EJ , et al. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 2001; 38 (5) 318-322
  CrossrefPubMedGoogle Scholar
• 22 Kastrinos F, Stoffel EM, Balmaña J, Steyerberg EW, Mercado R, Syngal S. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17 (8) 2044-2051
  CrossrefPubMedGoogle Scholar
• 23 Gylling AHS, Nieminen TT, Abdel-Rahman WM , et al. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 2008; 29 (7) 1351-1359
  CrossrefPubMedGoogle Scholar
• 24 Rouprêt M, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 2008; 54 (6) 1226-1236
  CrossrefPubMedGoogle Scholar
• 25 Grindedal EM, Møller P, Eeles R , et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 2009; 18 (9) 2460-2467
  CrossrefPubMedGoogle Scholar
• 26 Kilpivaara AP, Vahteristo P , et al. CHEK2 I157T Associates with familial and sporadic colorectal cancer. J Med Genet 2006; 43: e34
  PubMedGoogle Scholar
• 27 Kohlmann W, Gruber SB. Lynch syndrome. Gene reviews. Bethesda, MD: National Center Biotechnology Information; 2011
  Google Scholar
• 28 Kastrinos F, Mukherjee B, Tayob N , et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009; 302 (16) 1790-1795
  CrossrefPubMedGoogle Scholar
• 29 Wolff BG, Fleshman JW, Beck DE , et al. The ASCRS Textbook of Colon and Rectal Surgery. New York, NY: Springer; 2007: 525-542
  CrossrefGoogle Scholar
• 30 Song YM, Zheng S. Analysis for phenotype of HNPCC in China. World J Gastroenterol 2002; 8 (5) 837-840
  PubMedGoogle Scholar
• 31 Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64 (6) 430-433
  CrossrefPubMedGoogle Scholar
• 32 Barrow E, Robinson L, Alduaij W , et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009; 75 (2) 141-149
  CrossrefPubMedGoogle Scholar
• 33 Roa JC, Roa I, Correa P , et al. Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. J Gastroenterol 2005; 40 (1) 79-86
  CrossrefPubMedGoogle Scholar
• 34 ten Kate GL, Kleibeuker JH, Nagengast FM , et al. Is surveillance of the small bowel indicated for Lynch syndrome families?. Gut 2007; 56 (9) 1198-1201
  CrossrefPubMedGoogle Scholar
• 35 Schulmann K, Brasch FE, Kunstmann E , et al; German HNPCC Consortium. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 2005; 128 (3) 590-599
  CrossrefPubMedGoogle Scholar
• 36 Aarnio M, Sankila R, Pukkala E , et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81 (2) 214-218
  CrossrefPubMedGoogle Scholar
• 37 Vasen HFA, Stormorken A, Menko FH , et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001; 19 (20) 4074-4080
  CrossrefPubMedGoogle Scholar
• 38 Murphy HR, Armstrong R, Cairns D, Greenhalgh KL. Muir-Torre syndrome: expanding the genotype and phenotype—a further family with a MSH6 mutation. Fam Cancer 2008; 7 (3) 255-257
  CrossrefPubMedGoogle Scholar
• 39 Lynch HT, Lynch PM, Pester J, Fusaro RM. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med 1981; 141 (5) 607-611
  CrossrefPubMedGoogle Scholar
• 40 Czakó L, Tiszlavicz L, Takács R , et al. [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation]. Orv Hetil 2005; 146 (20) 1009-1016
  PubMedGoogle Scholar
• 41 Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet 2009; 46 (12) 793-802
  CrossrefPubMedGoogle Scholar
• 42 Hangaishi A, Ogawa S, Mitani K , et al. Mutations and loss of expression of a mismatch repair gene, hMLH1, in leukemia and lymphoma cell lines. Blood 1997; 89 (5) 1740-1747
  PubMedGoogle Scholar
• 43 Pineda M, Castellsagué E, Musulén E , et al. Non-Hodgkin lymphoma related to hereditary nonpolyposis colorectal cancer in a patient with a novel heterozygous complex deletion in the MSH2 gene. Genes Chromosomes Cancer 2008; 47 (4) (Issue 4) 326-332
  CrossrefPubMedGoogle Scholar
• 44 Hirano K, Yamashita K, Yamashita N , et al. Non-Hodgkin's lymphoma in a patient with probable hereditary nonpolyposis colon cancer: report of a case and review of the literature. Dis Colon Rectum 2002; 45 (2) 273-279
  CrossrefPubMedGoogle Scholar
• 45 Peled JU, Sellers RS, Iglesias-Ussel MD , et al. Msh6 protects mature B cells from lymphoma by preserving genomic stability. Am J Pathol 2010; 177 (5) 2597-2608
  CrossrefPubMedGoogle Scholar
• 46 Lucci-Cordisco E, Rovella V, Carrara S , et al. Mutations of the 'minor' mismatch repair gene MSH6 in typical and atypical hereditary nonpolyposis colorectal cancer. Fam Cancer 2001; 1 (2) 93-99
  PubMedGoogle Scholar
• 47 Edelmann W, Yang K, Umar A , et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997; 91 (4) 467-477
  CrossrefPubMedGoogle Scholar
• 48 Nilbert M, Therkildsen C, Nissen A, Akerman M, Bernstein I. Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum. Fam Cancer 2009; 8 (3) 209-213
  CrossrefPubMedGoogle Scholar
• 49 Brieger A, Engels K, Schaefer D , et al. Malignant fibrous histiocytoma is a rare Lynch syndrome-associated tumor in two German families. Familial Cancer 2011; 10 (3) 591-595
  CrossrefPubMedGoogle Scholar
• 50 Medina Arana V, Barrios del Pino Y, García-Castro C, González-Aguilera JJ, Fernández-Peralta A, González Hermoso F. Highly aggressive leiomyosarcoma associated with Lynch II syndrome: increasing the range of extracolonic cancers related with hereditary non-polyposis colonic cancer. Ann Oncol 2002; 13 (5) 807-808
  CrossrefPubMedGoogle Scholar